Pharmaceutical

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat PI.

Jul 1, 2025 - 06:01
FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency
The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat PI.
Read the original article

Tags:

Previous Article

From Lab Bench to Bedside: The Potential of Renewable Polymers to Revolutionize ...

Next Article

WHO accuses China of withholding Covid-19 genetic data

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: CVS Health to close clinical trial unit two years after launch

STAT+: CVS Health to close clinical trial unit two year...

May 17, 2023

Opinion: There is no epidemic of autism. It’s an epidemic of need

Opinion: There is no epidemic of autism. It’s an epidem...

Mar 24, 2023

STAT+: Here’s who’s profiting the most in health care

STAT+: Here’s who’s profiting the most in health care

Jan 2, 2024